Clinical trial
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With…
NCT00460603 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00460603 |
|---|---|
| Title | Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer |
| Official title | A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Combinations With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer Preceded By A Phase 1 Portion |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms |
| Intervention type | Drug |
| Interventions | bevacizumab, AG-013726, AG-013736 (axitinib) |
| Enrollment | 187 |
| Start date | Jan 1, 2006 |
| Primary completion | Apr 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Apr 16, 2007 |
| Last update posted | Dec 6, 2013 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: